Febril Nötropeni

Yazarlar

Yağmur Başak Çubukçu
Hatice Asoğlu
https://orcid.org/0009-0000-1366-5552

Özet

Febril nötropeni, kemoterapi alan kanser hastalarında hızlı tanı ve tedavi gerektiren onkolojik bir acil durumdur. Bu bölümde erişkin hastalarda febril nötropeninin tanısı, risk sınıflaması, tedavisi ve önlenmesi güncel kılavuzlar, randomize kontrollü çalışmalar ve meta-analizler temelinde özetlenmektedir. Başlangıç yönetiminin temeli sistematik değerlendirme, en az iki set kan kültürü ve ampirik antibiyotiğin ilk bir saat içinde başlanmasıdır. Risk skorları tedavi yerinin belirlenmesine yardımcı olur ancak klinik değerlendirmenin yerini almaz; hemodinamik instabilite veya organ disfonksiyonu olan hastalar hastaneye yatırılmalıdır. Yüksek riskli hastalarda yerel direnç epidemiyolojisine göre seçilen antipsödomonal β-laktam monoterapisi standart yaklaşımdır; karbapenemaz üreten bakterilerde tedavi direnç mekanizması ve antibiyograma göre seçilmelidir. Seçilmiş, stabil ve ateşsiz hastalarda ampirik tedavi nötrofil toparlanması beklenmeden kesilebilir. Antifungal stratejide beklenen nötropeni süresi, önceki profilaksi, görüntüleme ve biyobelirteçler belirleyicidir; önlemede granülosit koloni stimülan faktör ve florokinolon profilaksisi öne çıkmaktadır.

 

Referanslar

Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Annals of Oncology. 2016;27(Suppl 5): v111–v118. doi:10.1093/annonc/mdw325

Sandherr M, Stemler J, Schalk E, et al. 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies. The Lancet Regional Health – Europe. 2025;51: 101214. doi:10.1016/j.lanepe.2025.101214

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2011;52(4): e56–e93. doi:10.1093/cid/cir073

Taplitz RA, Kennedy EB, Flowers CR. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update summary. Journal of Oncology Practice. 2018;14(4): 250–255. doi:10.1200/JOP.18.00016

Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10): 2258–2266. doi:10.1002/cncr.21847

Carmona-Bayonas A, Jimenez-Fonseca P, de Castro EM, et al. SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). Clinical and Translational Oncology. 2019;21(1): 75–86. doi:10.1007/s12094-018-1983-4

Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer. 2011;47(1): 8–32. doi:10.1016/j.ejca.2010.10.013

Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98(12): 1826–1835. doi:10.3324/haematol.2013.091025

Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2015;33(28): 3199–3212. doi:10.1200/JCO.2015.62.3488

Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology. 2000;18(16): 3038–3051. doi:10.1200/JCO.2000.18.16.3038

Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. Journal of Clinical Oncology. 2015;33(5): 465–471. doi:10.1200/JCO.2014.57.2347

Cooksley T, Font C, Thursky K, et al. Febrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition: a MASCC consensus statement. Supportive Care in Cancer. 2026;34(8): 813. doi:10.1007/s00520-026-11045-7

Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database of Systematic Reviews. 2013;(6): CD003038. doi:10.1002/14651858.CD003038.pub2

Beyar-Katz O, Dickstein Y, Borok S, et al. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database of Systematic Reviews. 2017;(6): CD003914. doi:10.1002/14651858.CD003914.pub4

Averbuch D, Vanbiervliet Y, Baccelli F, et al. Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia. The Lancet Infectious Diseases. 2026;26(6): e232–e247. doi:10.1016/S1473-3099(25)00619-X

Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clinical Infectious Diseases. 2021;73(5): e1029–e1044. doi:10.1093/cid/ciab549

Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clinical Infectious Diseases. 2024; ciae403. doi:10.1093/cid/ciae403

Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. The New England Journal of Medicine. 1999;341(5): 312–318. doi:10.1056/NEJM199907293410502

Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine. 1999;341(5): 305–311. doi:10.1056/NEJM199907293410501

Vidal L, Ben Dor I, Paul M, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database of Systematic Reviews. 2013;(10): CD003992. doi:10.1002/14651858.CD003992.pub3

Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. The Lancet Haematology. 2017;4(12): e573–e583. doi:10.1016/S2352-3026(17)30211-9

de Jonge NA, Sikkens JJ, Zweegman S, et al. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial. The Lancet Haematology. 2022;9(8): e563–e572. doi:10.1016/S2352-3026(22)00145-4

Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clinical Infectious Diseases. 2009;48(8): 1042–1051. doi:10.1086/597395

Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. The New England Journal of Medicine. 2004;351(14): 1391–1402. doi:10.1056/NEJMoa040446

Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database of Systematic Reviews. 2014;(10): CD003039. doi:10.1002/14651858.CD003039.pub2

Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. Journal of Clinical Oncology. 2007;25(21): 3158–3167. doi:10.1200/JCO.2006.08.8823

Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology. 2005;23(6): 1178–1184. doi:10.1200/JCO.2005.09.102

Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database of Systematic Reviews. 2012;(1): CD004386. doi:10.1002/14651858.CD004386.pub3

Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. The New England Journal of Medicine. 2005;353(10): 977–987. doi:10.1056/NEJMoa044097

Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. The New England Journal of Medicine. 2005;353(10): 988–998. doi:10.1056/NEJMoa050078

Taplitz RA, Kennedy EB, Flowers CR. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update summary. Journal of Oncology Practice. 2018;14(11): 692–695. doi:10.1200/JOP.18.00366

Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. The New England Journal of Medicine. 2007;356(4): 348–359. doi:10.1056/NEJMoa061094

Yayınlanan

16 Kasım 2026

Lisans

Lisans